Assessment of Multidrug Resistance-Associated Protein 1 Activity in Healthy Volunteers and Alzheimer's Disease Patients Using Positron Emission Tomography

The primary objective of this study is to assess the **tissue activity** of multidrug resistance-associated protein 1 (MRP1) using positron emission tomography (PET) in both healthy volunteers and patients with **Alzheimer's disease**. Evaluating the activity of MRP1 is clinically relevant as it may provide insights into the role of this protein in drug resistance and its potential impact on therapeutic efficacy in Alzheimer's disease. Understanding MRP1 activity could contribute to the development of more effective treatment strategies for managing Alzheimer's disease by potentially overcoming drug resistance mechanisms.

The clinical trial involves **healthy volunteers** and patients diagnosed with **Alzheimer's disease**. The study population includes both male and female participants, with an age range spanning from 18 to 64 years. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria for the trial population, as well as any relevant lifestyle considerations such as diet, physical activity, or habits, have not been disclosed. Key inclusion or exclusion criteria are also not specified in the available data.

The clinical trial is a **phase I** pilot study designed to assess the tissue activity of multidrug resistance-associated protein 1 using positron emission tomography. This prospective, single-center study involves both healthy volunteers and patients diagnosed with **Alzheimer's disease**. The trial is set to commence recruitment on March 14, 2023, and is anticipated to conclude by January 1, 2031. The study employs a non-randomized, open-label design, focusing on the safety and preliminary efficacy of the investigational procedure.

Participants will undergo a series of study visits, beginning with an inclusion visit, which serves as the screening phase to determine eligibility based on predefined criteria. Following successful screening, participants will be scheduled for subsequent visits, which will include baseline assessments, imaging procedures, and safety evaluations. The frequency and number of follow-up visits will be determined by the study protocol, ensuring comprehensive monitoring of participants throughout the trial duration. The end-of-study visit will mark the completion of the participant's involvement, during which final assessments and evaluations will be conducted to gather conclusive data.

The expected length of participant involvement will vary depending on individual response and adherence to the study protocol. Conditions that may lead to early termination from the study include adverse events, withdrawal of consent, or non-compliance with study procedures. The trial aims to gather critical data on the investigational procedure's safety profile and its potential implications for future therapeutic applications in Alzheimer's disease management.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the **experimental medication**, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available. Additionally, details about drug administration, dosing schedules, and participant compliance monitoring are not included in the source data. As such, no further information can be offered regarding the substances involved in this clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, focusing on initial safety and efficacy assessments. The estimated recruitment start date is March 14, 2023, with an anticipated end date of January 1, 2031. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, typical Phase 1 trials often involve the collection of preliminary data on the intervention's effect on the disease. This may include the use of validated scales, laboratory tests, or patient-reported outcomes to measure changes in **biomarker** levels or symptom improvement. The schedule for measuring and collecting these parameters is typically aligned with the trial's timeline, ensuring systematic data collection at predefined intervals. The analysis of efficacy data will be conducted using appropriate statistical methods to determine the intervention's impact. The trial's design and methodology adhere to regulatory standards to ensure the reliability and validity of the findings.